Back to Anacor Homepage Developing Drug Candidates Through Boron Chemistry
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.
Investors overview.gif
Investor Relations Contact:
ir@anacor.com
Phone: 650-543-7575

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Anacor Pharmaceuticals, Inc.'s financial performance into perspective.

View all »Recent Releases

Jul 21, 2014
Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of KERYDIN in the United States

Jul 8, 2014
FDA Approves Anacor Pharmaceuticals' KERYDIN™ (Tavaborole) Topical Solution, 5% for the Treatment of Onychomycosis of the Toenails

View all »Events & Presentations

Jul 21, 2014 at 5:00 AM PT
Anacor Commercialization with Sandoz

Jun 2, 2014 at 3:30 PM ET
Jefferies 2014 Global Healthcare Conference

May 19, 2014 at 4:00 PM ET
UBS Global Health Care Conference

Receive Email Alerts

Sign up to receive e-mail alerts whenever Anacor posts new information to the site.



(ANAC): NASDAQ
Price: 16.45 Change: -0.46
High: 17.46 %Change: 2.720%
Low: 16.28 Volume: 545,300